BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//talks.cam.ac.uk//v3//EN
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:19700329T010000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:19701025T020000
RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
CATEGORIES:Meeting the Challenge of Healthy Ageing in the 21s
 t Century
SUMMARY:Prediction of Mortality in Older People\, and Indi
 vidualized Healthspan-Promoting Interventions  - P
 rofessor Georg Fuellen\, Rostock University Medica
 l Center\, Rostock\, Germany
DTSTART;TZID=Europe/London:20170223T111500
DTEND;TZID=Europe/London:20170223T114500
UID:TALK69828AThttp://talks.cam.ac.uk
URL:http://talks.cam.ac.uk/talk/index/69828
DESCRIPTION:In the first part of the talk\, we report the resu
 lts of Cox regression and Pearson correlation anal
 yses using data of the Study of Health in Pomerani
 a (SHIP)\, with mortality information of 1518 part
 icipants (113 of which died)\, over a time span of
  more than 10 years. While some of the Cox regress
 ion biomarkers were firmly established in many stu
 dies before\, others align with an ”integrated alb
 unemia” model of aging proposed recently.\nAnalysi
 s of existing longitidinal data is expected to yie
 ld biomarkers useful for future studies towards in
 dividualizing healthspan-promoting interventions.\
 nInterventions in rhesus demonstrate that healthy 
 aging can be promoted. In the form of caloric rest
 riction mimetics\, feasible diet and small-molecul
 e interventions are now on the horizon. These inte
 rventions must ultimately be combined in individua
 lized ways. In turn\, good (omics) biomarkers are 
 needed. I will therefore discuss the specific prob
 lems posed by trials for individualized healthspan
 -promoting interventions\, regarding the overall d
 esign\, choice of trial participants\, interventio
 ns\, endpoints and of the variables to be measured
 \, ranging from blood counts to omics data. A key 
 question is how to single out the variables that m
 ay qualify as the most useful biomarkers.
LOCATION:Online
CONTACT:Ilana Spilka
END:VEVENT
END:VCALENDAR